NovoCure
NVCR
296 hedge funds and large institutions have $5.38B invested in NovoCure in 2023 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 85 increasing their positions, 97 reducing their positions, and 52 closing their positions.
162% more call options, than puts
Call options by funds: $151M | Put options by funds: $57.8M
4.34% more ownership
Funds ownership: 80.54% → 84.88% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 52
2% less funds holding
Funds holding: 303 → 296 (-7)
12% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 97
13% less capital invested
Capital invested by funds: $6.2B → $5.38B (-$822M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$123M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$93.9M |
| 3 |
BlackRock
New York
|
+$57.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$42.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$24.5M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$24.2M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$20.8M |
| 4 |
Goldman Sachs
New York
|
-$9.59M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$8.02M |
NVCR Hedge Fund Activity: Q1 2023 in Review
296 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2023, worth a combined $5.38B — down 13% from $6.2B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of NVCR and 47 opened new positions — a net loss of 5 holders — while 97 trimmed existing stakes and 85 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $123M. The largest seller was Fiera Capital (Canada), cutting an estimated $24.5M.
- 296 institutional investors held NovoCure (NVCR) as of Q1 2023, down from 303 in Q4 2022.
- Funds reported $5.38B of NovoCure stock for Q1 2023, down 13% quarter-over-quarter.
- 47 funds opened new NovoCure positions in Q1 2023 and 52 closed out, a net change of -5 holders.
- The largest NovoCure buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $123M added.
- The largest NovoCure seller in Q1 2023 was Fiera Capital (Canada), an estimated $24.5M sold.
Based on aggregated 13F filings for Q1 2023.